 InPharm | NICE final draft "no" for Sanofi's Jevtana Pharma Times In final draft guidance, the National Institute for Health and Clinical Excellence (NICE) says it does not recommend Sanofi's Jevtana (cabazitaxel), in combination with prednisone or prednisolone, as a second-line treatment for prostate cancer. ... NICE rejects Sanofi's Jevtana Negative NICE guidance for Sanofi prostate cancer drug Sanofi's Jevtana Cancer Drug Rejected by UK Cost Agency |
